TrialSignal
Clinical trial intelligence report
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03029247
Status
COMPLETED
Phase
Phase 2
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
The ASCEND-BP study evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against epoetin alfa in managing blood pressure in hemodialysis patients with anemia due to CKD. The study was sponsored by GlaxoSmithKline and involved 105 participants, with a focus on the drug's impact on systolic blood pressure.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03029247
Indication
Anaemia
Modality
small molecule
Target
Anemia in Chronic Kidney Disease (CKD)
Intervention
Daprodustat, Epoetin alfa
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.